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The HIV-1 envelope glycoprotein is expressed on the viral membrane as a trimeric complex, formed by three gp120 surface
glycoproteins non-covalently associated with three membrane-anchored gp41 subunits. The labile nature of the association between gp120
and gp41 hinders the expression of soluble, fully cleaved, trimeric gp140 proteins for structural and immunization studies. Disruption of the
primary cleavage site within gp160 allows the production of stable gp140 trimers, but cleavage-defective trimers are antigenically dissimilar
from their cleaved counterparts. Soluble, stabilized, proteolytically cleaved, trimeric gp140 proteins can be generated by engineering an
intermolecular disulfide bond between gp120 and gp41 (SOS), combined with a single residue change, I559P, within gp41 (SOSIP). We
have found that SOSIP gp140 proteins based on the subtype A HIV-1 strain KNH1144 form particularly homogenous trimers compared to a
prototypic strain (JR-FL, subtype B). We now show that the determinants of this enhanced stability are located in the N-terminal region of
KNH11144 gp41 and that, when substituted into heterologous Env sequences (e.g., JR-FL and Ba-L) they have a similarly beneficial effect
on trimer stability. The stabilized trimers retain the epitopes for several neutralizing antibodies (b12, 2G12, 2F5 and 4E10) and the CD4-
IgG2 molecule, suggesting that the overall antigenic structure of the gp140 protein has not been adversely impaired by the trimer-stabilizing
substitutions. The ability to increase the stability of gp140 trimers might be useful for neutralizing antibody-based vaccine strategies based
on the use of this type of immunogen.
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The ability of human immunodeficiency virus type 1 (HIV-1)
to enter its target cell and establish an infection is dependent on
interactions between functional envelope glycoprotein (Env)
complexes on the virus and receptors on the host cell. The
HIV-1 Env complex is initially synthesized as the polyprotein
precursor gp160, which undergoes oligomerization, disulfide
bond formation and extensive glycosylation in the endoplasmic
reticulum (Earl et al., 1991), and is then proteolytically cleaved
into the surface (gp120) and transmembrane (gp41) subunits by
furin-like endo-proteases in the Golgi network (Fields et al.,⁎ Corresponding author. Fax: +1 212 746 8340.
E-mail address: jpm2003@med.cornell.edu (J.P. Moore).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2006.09.0461996; Hunter and Swanstrom, 1990). The resulting Env
complex is a trimer, with three gp120 proteins associated
non-covalently with three gp41 subunits. During the entry
process, gp120 interacts with the CD4 receptor, which triggers
conformational changes that facilitate gp120 binding to a
coreceptor, CCR5 or CXCR4 (Berger et al., 1999; Rizzuto et
al., 1998). These interactions promote extensive conforma-
tional changes in the gp41 subunit that drive the insertion of
the hydrophobic gp41 N-terminal region (fusion peptide) into
the host cell membrane. Subsequently, formation of the six-
helix bundle configuration of the three gp41 ectodomains
forces the juxtaposition of the viral and cell membranes,
promoting their fusion (Doms and Moore, 2000; Jones et al.,
1998; Melikyan et al., 2000; Moore and Doms, 2003; Sattentau
and Moore, 1991; Sullivan et al., 1998; Wu et al., 1996; Zhang
et al., 1999).
Fig. 1. (A) Schematic view of gp41 region showing the location of the fusion peptide (FP), heptad repeat regions 1 and 2 (HR1 and HR2), the transmembrane region
(TM) and the cytoplasmic tail (CT). The intramolecular disulfide bond is also shown. (B) Alignment of the N-terminus regions of KNH1144, JR-FL and Ba-L gp41,
highlighting the 5 amino acids (bold and shaded) in and near the HR1 region (underlined) that differ in JR-FL and B-aL when compared to KNH1144.
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confirmed by various lines of evidence (Blacklow et al.,
1995; Center et al., 2001, 2002; Chan et al., 1997; Chan and
Kim, 1998; Lu et al., 1995; Zhu et al., 2003), most recently
by cryo-electron microscopy (Zanetti et al., 2006; Zhu et al.,
2006). The trimer is held together by labile, non-covalent
inter-subunit interactions. The weak interactions between
gp120 and gp41, and between individual gp41 subunits, are
probably necessary for the conformational changes that drive
membrane fusion, but they complicate the generation of
soluble forms of Env trimers that are suitable for vaccine
research and structural studies. To obtain soluble Env trimers,
the transmembrane (TM) region and the cytoplasmic tail (CT)
are routinely deleted from gp41 to create gp140 proteins that
contain gp120 and the gp41 ectodomain (gp41ECTO). There are
different ways to stabilize the non-covalent inter-subunit
interactions: some groups mutate the cleavage site within
gp140 to make uncleaved oligomers (Chakrabarti et al., 2002;
Srivastava et al., 2002; Yang et al., 2000, 2002; Zhang et al.,
2001); our approach has been to engineer an inter-subunit
disulfide bond (SOS) (Binley et al., 2000) between gp120 andFig. 2. Trimer formation by cleaved, wild-type and mutant KNH1144 gp140 protei
SOSIP gp140 mutants containing the indicated single residue substitutions in the g
(C) KNH1144 SOSIP and SOS mutant gp140 s, as indicated. Each panel shows agp41, and an isoleucine to proline substitution at position 559
(I559P) in the N-terminal heptad region of gp41 ectodomain
(SOSIP) (Sanders et al., 2002) to promote gp41–gp41
association. We recently characterized a soluble, cleaved
SOSIP gp140 protein from the subtype A virus KNH1144
(Beddows et al., 2006). Compared to other SOSIP gp140s we
have studied, particularly from JR-FL, the KNH1144 protein
formed more homogenous trimers; the fewer monomers,
dimers, tetramers and aggregates present suggest that the
trimer form was unusually stable (Beddows et al., 2006). Here,
we have studied the molecular determinants of enhanced
trimer stability. We find that they lie within the N-terminal
region of gp41ECTO, an area with a well-documented role in
gp41–gp41 interactions (Center et al., 1997; Poumbourios et
al., 1997; Shugars et al., 1996). Specifically, we show that five
amino acid changes based on the KNH1144 sequence have a
trimer-stabilizing effect on heterologous gp140 proteins. The
introduction of these changes did not impair the exposure of
various neutralizing antibody epitopes on the resulting gp140
proteins, suggesting that the overall antigenic structure of the
trimer is not adversely affected.ns. (A) SOS and SOSIP versions of KNH1144 gp140 proteins. (B) KNH1144
p41 N-terminal region, compared with the wild-type KNH1144 SOSIP gp140.
BN-PAGE analysis, followed by Western blotting using MAb CA13.
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Specific amino acids in the N-terminal region of gp41ECTO
contribute to enhanced oligomerization of cleaved gp140 from
KNH1144
We recently reported that cleaved, SOSIP gp140 proteins
from the subtype A strain KNH1144 form unusually stable and
homogenous trimers compared to JR-FL SOSIP gp140, whichFig. 3. Trimer formation by cleaved, wild-type and mutant JR-FL SOS gp140
intermolecular disulfide bond (SOS) and the Ile to Pro substitution at position 559
gp140 proteins were analyzed using BN-PAGE and Western blotting with MAb CA
L543Q, N553S, Q567K and G588R, in the gp41 N-terminus region. (C) The JR-F
SOS gp140 mutant were analyzed by SDS-PAGE and Western blotting, followed
presence of DTT.is expressed as both dimers and trimers (Sanders et al., 2002).
The SOS gp140 protein from KNH1144 is also more stable than
the corresponding JR-FL construct, the latter being expressed as
a mixture of trimers, dimers and, predominantly, monomers
(Beddows et al., 2006; Binley et al., 2000). On purification, JR-
FL SOS gp140 yields mostly monomeric gp140 proteins as a
result of the instability of the gp41–gp41 interactions (Binley et
al., 2000). We therefore sought to determine why the KNH1144
gp140 was better able to form stable trimers.proteins. (A) Design of various chimeric and mutant JR-FL gp140 s. The
(I559P; SOSIP) are shown. (B) The indicated wild-type and mutant/chimeric
13. The designation NT 1–5 refers to substitution of the 5 amino acids M535I,
Lgp120–1144gp41(ECTO) SOS gp140 chimera and the JR-FL gp41 NT 1–5
by detection with MAb B13. The − and + symbols indicate the absence and
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Heptad Repeat 1 (HR1) region, plays a role in oligomerization
of gp140 proteins (Center et al., 1997, 2004; Poumbourios et al.,
1997). When the N-terminal regions of gp41 from KNH144 and
JR-FL were aligned, five amino acids were seen to differ, as
follows (KNH1144 vs. JR-FL): I535M, Q543L, S553N, K567Q
and R588G (Fig. 1). To determine, which, if any, of these five
differences contributed to the enhanced stability of KNH1144
trimers, we substituted each residue in KNH11144 SOSIP
gp140 with the corresponding one from JR-FL, then expressed
the mutant Env proteins and studied them on BN-PAGE gels.
The wild-type forms of KNH1144 SOS and SOSIP gp140
proteins were also analyzed, to allow a comparison with the
trimer-stabilizing effect of the I559P substitution in the SOSIP
version (Fig. 2A). In general, the amino acid substitutions
described below had similar effects whether they were made in
the SOS or the SOSIP gp140 background, so only a subset of
the results is depicted.
The S553N and R588G changes had little or no effect on
trimer formation by KNH1144 SOSIP gp140 (Fig. 2B, lanes 3
and 5), whereas the I535M substitution enhanced trimer
formation (Fig. 2B, lane 1), an observation we confirmed in
a larger-scale expression and purification study (data not
shown). In contrast, substitutions of glutamine and lysine at
positions 543 and 567 (Q543L and K567Q) destabilized the
KNH1144 SOSIP gp140 trimers (Fig. 2B, lanes 2 and 4). When
all five amino acids were substituted in the KNH1144 SOS and
SOSIP gp140 templates, the destabilizing effect on trimer
formation was pronounced. The extent of the increase in
monomer formation, compared to wild-type, was estimated to
be ∼45% and ∼60% for the KNH1144 SOSIP and SOS gp140
mutants, respectively (Fig. 2C, lane 1, SOSIP; lane 2, SOS;
compare with Fig. 2A). Hence, we conclude that the five amino
acid differences between the N-terminal regions of KNH1144
and JR-FL gp41 do influence the stability of cleaved gp140
trimers.Fig. 4. (A) The wild-type JR-FL SOS gp140 and (B) the JR-FL gp41 NT 1–5 SOS
BN-PAGE and Western blotting with MAb CA13. The mutant protein is predomiSubstitution of five amino acids from the N-terminal region of
KNH1144 gp41ECTO promotes JR-FL gp140 trimer formation
We used both the SOS and SOSIP versions of JR-FL gp140
as templates on which to explore the effects of the five amino
acid differences in the KNH114 gp41 ectodomain, to ensure we
took into account the additional, possibly complicating,
influence of the I559P change. In the first construct, a chimera,
the JR-FL gp120 subunit was combined with the KNH1144
gp41 ectodomain (JR-FLgp120–1144gp41 ECTO); the second
construct was a mutant JR-FL SOS gp140 in which the five
varying amino acids (positions 535, 543, 553, 567 and 588)
were substituted by the corresponding residues from KNH1144
(JR-FL gp41 NT 1–5); the third was another chimera in which
the C-terminal region of gp41ECTO from JR-FL was replaced by
the corresponding segment of KNH1144 gp41 (JR-FL gp120-
1144 gp41 CT) (Fig. 3A).
The various chimeric and mutant envelope glycoproteins
were expressed in HEK293T cells and analyzed on BN-PAGE
gels (Fig. 3B). JR-FL SOS gp140 was predominantly mono-
meric whereas the SOSIP gp140 formed dimers and trimers
(Fig. 3B, lanes 1 and 2). The insertion of gp41ECTO from
KNH1144 into the JR-FL SOS gp140 template stabilized the
trimeric form, with a reduction in the amount of monomers
present (Fig. 3B, lane 3). The same change, but made in the JR-
FL SOSIP gp140 context, had a lesser effect (Fig. 3B, compare
lanes 2 and 4). Swapping the C-terminal region of gp41ECTO in
either SOS or SOSIP JR-FL gp140 had no visible effect on
oligomerization (Fig. 3B, compare lane 1 to lane 5 and lane 2 to
lane 6). In contrast, oligomer formation by JR-FL SOS or
SOSIP gp140 was increased by the substitution of the five
varying amino acids in gp41ECTO with the corresponding
residues from KNH1144 (M535I, L543Q, N553S, Q567K and
G588R) (Fig. 3B, compare lane 7 to lane 1 and lane 8 to lane 2).
Taken together, these results confirm that the trimer-promoting
determinants of KNH1144 are located in the N-terminal regiongp140 mutant were analyzed by size-exclusion chromatography followed by
nantly trimeric, the wild-type protein mostly monomeric.
Fig. 5. (A) Representative SPR analysis of the binding of JR-FL SOS gp140 and the gp41 NT 1–5 SOS gp140 mutant to the following test agents: CD4-IgG2, b12,
2G12, 2F5, 4E10, 17b±D1D2 CD4 PA-1 and b6. The y-axis shows the SPR response unit (RU), the x-axis the time in seconds (s). (B) Injected samples from the
BIAcore machine were manually collected after the ligand-binding analysis, then analyzed by BN-PAGE. The wild-type JR-FL SOS gp140 and the gp41 NT 1–5 SOS
gp140 mutant proteins are shown, from a representative experiment, one using the PA-1 MAb.
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Table 1
SPR binding of WT and mutant forms of trimeric JR-FL gp140 proteins to
various monoclonal antibodies or CD4-IgG2
Test agent WT SOS gp140 gp41 NT 1–5 SOS
gp140 mutant
Mean RU±SD
(t=180 s a)
Mean RU±SD
(t=180 sa)
CD4-IgG2 212±8 b 224±13b
b12 223±6 195±10
2G12 269±7 278±15
2F5 191±8 216±6
4E10 83±4 94±5
PA-1 242±11 123±10
b6 391±14 233±11
17b 39±5 14±2
17b (+DID2 CD4) 237±8 399±18
a End-of-injection time (t) in seconds (s).
b MeanRU±SD based on three experiments, all using 5 nM of analyte.
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trimers can be conferred upon a heterologous gp140, JR-FL, by
altering the specific residues that differ between the two
proteins. Further studies showed that all five changes were
necessary for creating an optimally stable and homogenous JR-
FL gp140 trimer; various combinations of the five changes had
negligible or partial effects (data not shown).
To ascertain whether the chimeric/mutant proteins were fully
cleaved, we analyzed the JR-FLgp120-KNH1144gp41(ECTO)
SOS gp140 chimera and the JR-FL gp41 NT 1–5 SOS gp140
mutant, using Sodium-dodecyl sulfate polyacrylamide electro-
phoresis (SDS-PAGE) (Fig. 3C). Under denaturing conditions,
both gp140 proteins were resolved as monomers (lanes 1 and 3).
When DTTwas added to reduce the SOS disulfide bond, release
of the gp120 subunit was complete (lanes 2 and 4), along with
gp41ECTO (which is not detectable by the b13 MAb used for
blotting). Hence aberrantly linked, uncleaved products do not
contribute to the enhanced oligomerization of JR-FL gp140
conferred by substitution of the residues from the KNH1144
gp41 N-terminal region. The stabilized, mutant proteins are
fully cleaved.
To further assess the formation and stability of JR-FL gp41
NT 1–5 SOS gp140 trimers, this protein and JR-FL SOS gp140
were purified using lectin-affinity and size-exclusion chroma-
tography (SEC) techniques. The SEC-fractionated aliquots were
then resolved by BN-PAGE (Fig. 4). The JR-FL SOS gp140
protein was predominantly a monomer (Fig. 4A) whereas a
much greater proportion of the Env species present in JR-FL
gp41 NT 1–5 SOS migrated as well-resolved trimers (Fig. 4B;
compare lanes 11–16 with the corresponding lanes in Fig. 4A).
A densitometric analysis of the resolved gp140 trimer, dimer
and monomer fractions on BN-PAGE was combined with BCA
quantification of the pooled SEC fractions (trimer, dimer and
monomer), to estimate the change in each gp140 species.
Compared to the wild-type JR-FL SOS gp140 protein, trimer
formation by JR-FL gp41 NT 1–5 SOS gp140 was increased by
∼20% and dimer formation by ∼10%, whereas the monomer
content was reduced by ∼50%.
Antigenic properties of the wild-type JR-FL SOS and stabilized
JR-FL gp41 NT 1–5 SOS mutant gp140s
To determine whether the antigenicity of the mutant JR-FL
gp140 had been altered by the introduction of the trimer-
stabilizing substitutions, we used SPR methods to study its
binding of various antibodies, in comparison to the wild-type
gp140. In these studies, biotinylated Protein G was immobilized
onto a Streptavidin (SA)-coated chip, which was then used to
capture various agents via their Fc regions. The CD4-IgG2
protein (used as a surrogate for CD4) and the following MAbs
were all studied: b12 (neutralizing, anti-CD4BS), 2G12
(neutralizing, high-mannose epitope on the ‘silent face’), 2F5,
4E10 (both neutralizing, anti-gp41), PA-1 (non-neutralizing,
anti-V3), b6 (non-neutralizing, anti-CD4BS) and 17b (non-
neutralizing, CD4-induced epitope). Equal molar amounts of
purified wild-type andmutant gp140 trimers (>90% purity) were
then injected at 10 μl/min, to react with the immobilized MAbs.Both the wild-type SOS gp140 and the mutant gp41 NT
1–5 SOS gp140 bound CD4-IgG2 similarly (Fig. 5A and
Table 1). Their reactivities with b12 and 2G12 were also
similar, with similar response unit (RU) values at the end-of-
injection time (t=180 s). The two neutralizing anti-gp41
MAbs, 2F5 and 4E10, also bound similarly to the two gp140
proteins (Fig. 5A and Table 1). In the absence of sCD4
(D1D2-CD4), neither gp140 protein bound efficiently to MAb
17b, but when D1D2-CD4 was added, the 17b epitope was
induced on both proteins. The extent of the induction was
greater for the stabilized trimer than for the wild-type protein
(25-fold compared to 5-fold, respectively; Fig. 5A and Table
1). The non-neutralizing MAbs PA-1 and b6 bound less
efficiently to the stabilized trimer than to its wild-type
counterpart (Fig. 5A and Table 1). We are presently
investigating the basis for this observation in more detailed
studies that use a variety of techniques.
To ensure that we were comparing the MAb binding
properties of two trimer variants (wild-type and stabilized),
the injected gp140 samples used in the ligand-binding assays
were manually collected from the BIAcore X system and
analyzed using BN-PAGE. Both gp140 proteins were substan-
tially trimeric, even after passage through the BIAcore system
(Fig. 5B).
Substitution of four amino acids in N-terminal region of
gp41ECTO also increases the stability of SOS gp140 from
HIV-1 Ba-L
To test whether the trimer-stabilizing effect of the above five
gp41 amino acids was a generalized phenomenon, we studied
another subtype B Env protein, Ba-L. Like JR-FL, Ba-L
contains Met, Leu, Asn and Gln residues at positions 535, 543,
553 and 567, respectively. However, at position 588, Ba-L
contains Arg, as does KNH1144 (Fig. 1). We therefore
introduced the four non-cognate amino acids from KNH1144
into the N-terminal region of Ba-L (M535I, L543Q, N553S,
Q567K) to construct a mutant Ba-L gp41 NT 1–4 SOS gp140
protein.
Fig. 6. Stabilizing cleaved Ba-L SOS gp140 trimers. (A) The wild-type Ba-L
SOS gp140 and the mutant Ba-L gp41 NT 1–4 SOS gp140 proteins were
analyzed by BN-PAGE and Western blotting with MAb CA13. (B) The same
proteins were analyzed by SDS-PAGE and Western blotting, followed by
detection with MAb B13. The − and + symbols indicate the absence and
presence of DTT.
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gp140, like JR-FL, was a mixture of monomers, dimers and
trimers (Fig. 6A, lane 1). However, the mutant containing the
above four amino acid substitutions was predominantly trimeric
(Fig. 6A, lane 2), with >40% reduction in monomer formation.
No individual substitution had as pronounced an effect as the
quadruple combination (data not shown). The enhanced
trimerization of the mutant Ba-L gp41 NT 1–4 SOS gp140
was not attributable to the presence of aberrantly cross-linked
proteins, as shown by SDS-PAGE under reducing and non-
reducing conditions (Fig. 6B). Thus, under denaturing condi-
tions, in the absence of the reducing agent, the mutant protein
resolved as monomeric gp140; in the presence of DTT,
reduction of the disulfide bond dissociated the gp140 into its
constituent subunits (as in Fig. 3C, only the gp120 component is
detected in this analysis).
Taken together, these results suggest that modifications of a
few selected amino acids in the N-terminal region of gp41 can
improve the stability of gp140 trimers and that the finding might
be generalizable to diverse HIV-1 genotypes.
Discussion
Here, we have identified residues in the N-terminal region of
the gp41 ectodomain that influence the stability of trimeric
forms of the HIV-1 gp140 glycoprotein, particularly the trimersthat most, but of course incompletely, resemble the native form
of the Env complex. The residues were found by inspection of
the sequence of gp41ECTO from a subtype A SOSIP gp140
(KNH1144) that formed stable, cleaved trimers with unusual
efficiency. Comparison of this sequence with that of JR-FL, a
strain from which homogenous trimers are less easily made,
identified five variable residues in a plausibly relevant region of
gp41ECTO that lay in and around HR1. Substitution of those five
residues in KNH1144 gp140 by the corresponding ones from
JR-FL destabilized the resulting gp140 trimers. Conversely, and
of more relevance, formation of JR-FL gp140 trimers could be
considerably improved when the variable residues from
KNH1144 were introduced in place of the JR-FL residues.
The same approach also improved trimer formation in the
context of the Ba-L sequence, suggesting that our observation is
likely to be generally relevant for making stable, cleaved gp140
trimers. Substituting naturally variable amino acids may be a
less invasive way to promote trimer stabilization than
previously described alternatives, such as the use of hetero-
logous trimerization domains (Yang et al., 2000, 2002), or the
insertion of the SIV gp41 N-terminal region to make a HIV–
SIV chimeric envelope glycoprotein (Center et al., 2004).
The effect of substituting the KNH1144 gp41 residues into
JR-FL and Ba-L is to reduce the heterogeneity of the oligomeric
forms of SOS gp140 proteins when they are expressed as
unpurified culture supernatants. Thus there was a marked
decrease in the amount of monomers present, lesser but sill
notable decreases in dimers, tetramers and high-molecular
weight aggregates and, of most relevance, an increase in the
proportion of trimers. When the stabilized JR-FL SOS gp140
protein was purified by lectin-affinity and size-exclusion
chromatography, the amounts of monomers, tetramers and
aggregates were reduced, whereas trimers were markedly more
abundant and a small increase in the amount of dimers was also
apparent. We believe that the dimers are likely to be dissociation
products of trimers that arise during the purification process.
This would not be too surprising, since the increase in trimer-
stability is presumably only relative, not absolute, compared to
the wild-type protein.
Structural and biophysical studies will be necessary to
determine how the amino acid substitutions in the gp41
N-terminal region increase the formation or stability of gp140
oligomers, particularly trimers. We have noted that some of the
amino acids in the KNH1144 N-terminal region have longer
side chains than their JR-FL counterparts (KNH1144 vs. JR-FL:
Q543L, K567Q and R588G). It is also noteworthy that the
S553, K567 and R588 residues in KNH1144 have greater α-
helix-stabilizing propensities than the corresponding residues,
N553, Q567 and G588, in JR-FL. Hence alterations in the size
or the nature of the side chains may strengthen localized helix-
to-helix packing interactions in a way that stabilizes gp140
oligomers. As noted above, additional studies will be required
to investigate this possibility, however.
We observed that both the wild-type JR-FL SOS gp140 and
the stabilized JR-FL gp41 NT 1–5 SOS gp140 mutant bound
similarly to neutralizing antibodies and proteins (b12, 2G12,
2F5, 4E10 and CD4-IgG2). Hence the overall antigenic
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influenced by the sequence changes introduced into gp41. We
have also noted that the stabilized JR-FL trimers bound non-
neutralizing antibodies (PA-1, b6 and 17b) to a lesser extent
than the corresponding wild-type trimers. More detailed studies
are required to confirm, extend and understand the structural
basis of this observation, but any effect must be quite subtle in
nature, given the proximity and similarity of the b6 and b12
epitopes (Pantophlet et al., 2003). Whether stabilizing the
conformation of gp140 trimers is advantageous for use of these
proteins as vaccine immunogens is now under investigation.
Materials and methods
Reagents
CD4-IgG2 (PRO 542) (Allaway et al., 1995) and monoclonal
antibody (MAb) PA-1 were provided by Dr. William Olson
(Progenics Pharmaceuticals). Soluble D1D2-CD4 (sCD4-183, 2
domain) (Garlick et al., 1990) was obtained from the NIH AIDS
Research and Reference Program.MAbCA13 (ARP3119), from
Ms C. Arnold, was provided by the EU Programme EVA
Centralized Facility for AIDS Reagents, NIBSC, UK (AVIP
Contract Number LSHP-CT-2004-503487).MAbs 2G12 (Calar-
ese et al., 2003; Trkola et al., 1996), 2F5 (Parker et al., 2001;
Zwick et al., 2001) and 4E10 (Cardoso et al., 2005; Zwick et al.,
2001) were obtained from Hermann Katinger, MAb 17b (Thali
et al., 1993) from James Robinson and MAb b12 (Burton et al.,
1994) from Dennis Burton. The hybridoma for the production of
MAb B13 (HIV-1 gp160 Hyb, Chessie 13–39.1) (Abacioglu et
al., 1994) was obtained fromNIHAIDS Research and Reference
Program (donated by George K. Lewis).
Plasmids and construction of chimeric and mutant env genes
Various HIV-1 env genes, cloned into the high-level
mammalian expression vector pPPI4, were used for expression
of soluble gp140 glycoproteins as previously described. Furin
was expressed from pcDNA3.1-Furin (Binley et al., 2000;
Sanders et al., 2000). The HIV-1 Env subtype A clone
KNH1144 (accession number AF457066) (Beddows et al.,
2006) and the subtype B clones JR-FL and Ba-L have been
described previously (Binley et al., 2000). In domain-swap
experiments, the JR-FL gp41 ectodomain was replaced with the
corresponding region of KNH1144 gp41, using EcoRI and
HindIII restriction enzymes, followed by repair of the restriction
sites and verification of the sequences. Specific amino acid
substitutions were made using the QuikChange® II XL site-
directed mutagenesis kit (Stratagene Inc., La Jolla, California)
and the appropriate primers. The introduced mutations were
verified by sequencing.
Transfection and expression of soluble gp140 envelope
glycoproteins
The Human Embryonic Kidney cell line HEK293Twas used
for expression of the various envelope glycoproteins bytransient transfection, as previously described (Binley et al.,
2000; Sanders et al., 2000, 2002). HEK293T cells were grown
in Dulbecco's modified Eagle's medium (DMEM, Gibco)
supplemented with 10% fetal calf serum, penicillin, streptomy-
cin and L-glutamine. Transient transfections were performed
using Polyethylenimine (PEI) (Polysciences Inc., Warrington,
PA) (Boussif et al., 1995; Kirschner et al., 2006). For each
small-scale transfection, 7 μg of env DNA and 3.5 μg of furin
DNA were used. Five hours post-transfection, the 293T cells
were washed and the media replaced with DMEM containing
0.05% bovine serum albumin (BSA), antibiotics (penicillin,
streptomycin) and L-glutamine. Forty-eight hours post-transfec-
tion, the supernatant was collected and filtered using a 0.45 μm
filter. A cocktail of protease inhibitors (Roche Diagnostics,
Indianapolis, IN) was added before concentration of the
supernatant by >20-fold using the Amicon ultracentrifugal
filter system (Millipore, Billerica, MA). Aliquots of concen-
trated supernatant were analyzed by polyacrylamide electro-
phoresis, or stored at −80 °C for future study.
Purification of soluble envelope glycoproteins
Supernatants (1 l) from transfected HEK293T cells were
concentrated by >20-fold then processed by Lectin-affinity
chromatography. The column eluate was then size-fractio-
nated using an analytical Superose™ 6 column (GE
Amersham Pharmacia, Piscataway, NJ) equilibrated with
phosphate-buffered saline (PBS; 100 mM NaCl, 50 mM
sodium phosphate, pH 7.0). The column was calibrated with
protein standards of known molecular weights (HMW Gel
Filtration Calibration Kit; Amersham Pharmacia, Piscataway,
NJ). Fractions (200 μl) were collected and analyzed using
Blue-native polyacrylamide electrophoresis (BN-PAGE) and
SDS-PAGE. Quantification of proteins was carried out
using the BCA quantification kit (Pierce) with known BSA
standards.
BN-PAGE, SDS-PAGE and Western blot analysis
BN-PAGE was performed as described previously (Schulke
et al., 2002). Concentrated culture supernatants or purified
protein samples were diluted with an equal volume of a loading
buffer containing 100 mM 4-(N-morpholino) propane sulfonic
acid (MOPS), 100 mM Tris–HCl (pH 7.7), 40% glycerol, 0.1%
Coomassie blue, and loaded onto a 4–12% Bis–Tris NuPAGE
gel (Invitrogen). Gel electrophoresis was performed at 100 V
for 3 h using 50 mM MOPS, 50 mM Tris (pH 7.7) as
electrophoresis buffer. SDS-PAGE was performed as described
previously (Schulke et al., 2002). Reduced and non-reduced
samples were prepared in Laemmli sample buffer (62.5 mM
Tris–HCl, pH6.8, 2% SDS, 25% glycerol, 0.01% DTT) and
boiled for 5 min in the presence or absence of 50 mM
dithiothreitol (DTT), respectively.
Western blot analyses were performed as described elsewhere
(Schulke et al., 2002). Following transfer, the polyvinylidene
difluoride (PVDF) membrane was destained, then probed using
anti-Env MAbs CA13 (ARP3119) or B13, followed by
207A.K. Dey et al. / Virology 360 (2007) 199–208horseradish peroxidase-labeled anti-mouse immunoglobulin G
(IgG) (Kirkegaard and Perry Labs), at a final concentration of
0.2 μg/ml. The bound MAbs were detected using the Western
Blot Chemiluminescence Reagent Plus system (Perkin-Elmer
Life Sciences, Boston, MA). Protein mixtures containing
Thyroglobulin (669 kDa), Ferritin (440 kDa), Catalase
(232 kDa), Lactate dehydrogenase (140 kDa) and BSA
(66 kDa) (Amersham Biosciences) were used as standard
markers for native gels. For denaturing electrophoresis, the
MultiMark® multi-colored standard (Invitrogen) was used.
BIAcore surface plasmon resonance (SPR)
The BIAcore X system (BIAcore Inc, Uppsala, Sweden) was
used for comparison of the JR-FL WT vs. mutant gp140 env
binding to various monoclonal antibodies and CD4-IgG2. All
assays were performed at 25 °C using HBS-EP buffer (10 mM
HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% [v/v]
Surfactant P20; BIAcore, Uppsala, Sweden), which was
degassed for 1 h before use. The flow-rate was maintained at
10 μl/min. A BIAcore streptavidin (SA) chip was used for
capturing ∼1000 response units (RU) of biotinylated protein G
(Pierce) in both the experimental and the control flow-cells.
Biotin was then used to block the uncoated streptavidin surface
on both flow-cells. In the experimental cell, ∼1000 RU of
various MAbs and CD4-IgG2 were directionally captured onto
the surface-attached biotinylated Protein G via their Fc regions.
Purified envelope glycoproteins (5 nM) were then injected for
analysis of their ligand-binding properties. For study of the
CD4-induced binding of MAbs directed to the CD4i-epitope,
D1D2-CD4 (at a 6-molar excess concentration) was incubated
with the envelope glycoprotein for 1 h at room temperature
before injection. Following each run, the sensor surface was
regenerated using two 10 μl injections of 10 mM Glycine–HCl,
pH 3.0. For each analyte, association was measured for 180 s,
dissociation for a further >500 s. All binding studies were
performed three times (n=3) with good reproducibility. The
data were analyzed using BIAevaluation software 3.2 (BIAcore
Inc). To correct for refractive index changes and instrument
noise, the response data from the control flow-cell were
subtracted from those obtained from the experimental flow-
cell. For comparison of the antigenicity profiles of the wild-type
and mutant gp140 proteins, the end-of-injection RU values±SD
(n=3) are reported.
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